GATC Health Featured in Healthcare Business Today

GATC Health continues to garner attention from industry press, this time with a feature article in Healthcare Business Today.

The article, titled “Artificial Intelligence That ‘thinks’ Like Human Biology Advances Disease Detection, Treatment and Prevention,” is a resounding verification of both GATC Health’s industry leading technology and its place in the new world of personalized, predictive and precision healthcare.

From the article:

“GATC Health is a rising star in this sector, and in a very short time has managed to productize its technology for consumer markets while expediting drug discovery and development for pharma partners. The company focuses on Predictive Multiomics™, which studies the various biomes, or biological components (genome, proteome, transcriptome, etc.) to predictively model what may happen when a disease or treatment is given to a virtual, digital human.”

Read the full article:

https://www.healthcarebusinesstoday.com/artificial-intelligence-that-thinks-like-human-biology-advances-disease-detection-treatment-and-prevention

About GATC HealthGATC Health is a pioneering technology company using Predictive Multiomics™ to advance drug discovery and improve human health. GATC Health’s proprietary Multiomic Advanced Technology™ (MAT) sequences an individual’s DNA, reading the entire genome and analyzing the full data set of “omics,” including genomics, proteomics, microbiomics and others. A complete understanding of a person’s genetics combined with the evaluation of other omics yields the most comprehensive individual health analysis available, which can lead to fast-tracking drug development, pre-screening clinical trial participants, identifying new drugs and repurposing existing treatments. GATC Health’s innovative technology takes healthcare from reactive to predictive—it is truly personalized medicine. For more information about GATC Health, visit www.GATCHealth.com.

Disclaimer

The information set forth herein is presented for informational purposes only and should not be deemed an offer to sell securities.  This presentation contains information which the Company believes to be correct, including certain financial information and projections, but the Company does not guarantee as to the accuracy or completeness of such information.  The Company reserves the right to modify or amend the information contained herein.